Was betrifft es? Warum ist das wichtig?

Study insurance or liability coverage provides:

  • Researchers with financial protection against damages due to study conduct
  • Study participants with financial compensation, should they suffer harm due to study participation

 

 

Study insurance or liability coverage:

  • Is required for all studies. Overall requirements may highly depend on the expected risk to study participants (e.g. study risk categories)
  • Is either covered by the hospital/institution or an additional third-party insurer
  • Must cover damage / claims occurring up to 20 years after the completion of the study

 

 

Exceptions to liability coverage may arise if SP-INV and or Site-INV malpractice and/or negligence can be proven.

 

 

Was muss ich befolgen?

As a SP-INV, make yourself familiar with insurance requirements at your institution.

 

Address issues such as:

  • Does your hospital provide insurance that covers your planned study? If not, you will have to acquire additional third-party insurance
  • For study approval, a certificate of insurance must be included in an Ethics Committee (EC) submission, and if applicable in a Swissmedic submission

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – see in particular

  • Insurance template

References

ICH GCP E6(R3) – see in particular guidelines

  • 3.14 Trial insurance
  • Appendix B.15 Financing and insurance

ISO 14155:2020 Medical devices  (access liable to cost) - see in particular section

  • 5.6.2. Ethics submission 

 

Declaration of Helsinki – see in particular principle

  • 15 Subject compensation

 

Swiss Law

HRA – see in particular articles

  • Art. 19 and 20 Coverage

ClinO – see in particular articles

  • Art. 13 Requirement for liability coverage
  • Art. 14 Protection of the injured party
  • Annex 3 Ethics application

HRO – see in particular article

  • Annex 2 Ethics application
Abkürzungen
  • ClinO – Clinical Trials Ordinance
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • HRA – Human Research Act
  • HRO – Human Research Ordinance
  • ICH-GCP – International Council for Harmonisation - Good Clinical Practice
  • ISO – International Organization for Standardization
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor-Investigator
Development ↦ Management ↦ Study Management ↦ Insurance
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Management ↦ Study Management ↦ Insurance

Please note: the Easy-GCS tool is currently under construction.